Chronic inflammation, imbalance of proteolytic and anti-proteolytic activities, oxidative stress, and apoptosis of lung structural cells contribute to the pathogenesis of COPD. Prostacyclin protects cells against apoptosis, has anti-inflammatory properties, partially prevents cigarette smoke extract (CSE)-induced apoptosis of the pulmonary endothelium, and thus may be relevant in the pathogenesis of emphysema. We determined whether a synthetic stable prostacyclin analog, beraprost sodium (BPS), attenuates the development of CSE-induced emphysema and elucidated the molecular mechanisms involved in its effect. Sprague-Dawley rats were treated with BPS and injected with CSE once a week for 3 wk. We measured the DNA damage of cells, the expression of caspase-3, and the activity of matrix metalloproteinase (MMP)-2 and MMP-9. We also analyzed TNF␣ and IL-1␤ concentrations and the serum antioxidant activity. BPS prevented the development of CSE-induced emphysema, resulting in significant attenuation in alveolar enlargement and pulmonary parenchymal destruction. BPS inhibited pulmonary apoptosis and induction of MMP-2 and MMP-9 activity. Moreover, the protective effect of BPS was associated with a reduction of the expression of proinflammatory cytokines including TNF␣ and IL-1␤ and a normalized biological oxidant activity. BPS introduces all these events, probably by activating cAMP signaling through acting specific prostacyclin receptors. In conclusion, BPS protects against the development of CSE-induced emphysema by attenuating apoptosis, inhibiting proteolytic enzyme activity, reducing inflammatory cytokine levels, and augmenting antioxidant activity. BPS may potentially represent a new therapeutic option in the prevention of emphysema in humans in prospect. apoptosis; inflammation; rat; oxidative stress; matrix metalloproteinase CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is a major cause of chronic morbidity and mortality throughout the world. It is currently the fifth leading cause of death worldwide (27), and a further increase in its prevalence and mortality is predicted in the coming decades (19). The pathobiology of emphysema involves chronic inflammation of airways (5, 10), imbalance of proteolytic and anti-proteolytic activities (4, 6, 7), and oxidative stress (36). Recently, a role of the immune system in the pathogenesis of COPD has been proposed (2, 33), and several investigators reported apoptosis of structural cells in the lungs of patients with COPD (13, 20, 38) and experimental emphysema (3, 28, 36). Prostacyclin (PGI 2 ) is a major product of endothelial cells via the cyclooxygenase and PGI 2 synthase (PGI 2 S) enzymes (31). PGI 2 protects cells against apoptosis (8, 11), has antiinflammatory properties (23), and partially prevents cigarette smoke extract (CSE)-induced apoptosis of the pulmonary endothelium in vitro and in a murine transgenic model of lungspecific PGI 2 overexpression (24). Of interest, CSE suppressed PGI 2 S expression in human pulmonary microvascular endothelial cells (24).
Prostacyclin (PGI 2 ) is a major product of endothelial cells via the cyclooxygenase and PGI 2 synthase (PGI 2 S) enzymes (31) . PGI 2 protects cells against apoptosis (8, 11) , has antiinflammatory properties (23) , and partially prevents cigarette smoke extract (CSE)-induced apoptosis of the pulmonary endothelium in vitro and in a murine transgenic model of lungspecific PGI 2 overexpression (24) . Of interest, CSE suppressed PGI 2 S expression in human pulmonary microvascular endothelial cells (24) .
Beraprost sodium (BPS) is a synthetic PGI 2 analog that is chemically and metabolically more stable than PGI 2 . Here, we investigate whether the stable PGI 2 analog BPS, by inhibiting alveolar cell apoptosis and other molecular pathogenesis pathways, protects against experimental emphysema.
MATERIALS AND METHODS

Preparation of CSE
CSE was prepared as previously reported (24) with some modifications. Briefly, one cigarette (Marlboro, Philip Morris Companies) was burned, and the smoke passed through a filter for removing particles and bacteria into a vessel containing PBS (1 ml/1 cigarette) using a vacuum pump. The CSE-PBS solution was prepared fresh for each set of experiments.
Experimental Protocols
The animal protocol was approved by the Animal Care and Use Committee of Shinshu University. Six-week-old male Sprague-Dawley rats (weight range between 200 and 250 g) were randomly selected and divided into four groups (n ϭ 6 in each group): 1) control group, 2) CSE group, 3) CSE ϩ 100 g ⅐ kg Ϫ1 ⅐ day Ϫ1 of BPS (BPS-1 group), and 4) CSE ϩ 200 g ⅐ kg Ϫ1 ⅐ day Ϫ1 of BPS (BPS-2 group). The control rats were injected intraperitoneally with 1 ml of vehicle (normal saline) on day 1, 8, and 15 . One milliliter of the CSE-PBS solution was injected intraperitoneally on day 1, 8, and 15, and BPS (prepared in 2 ml of normal saline; Astellas Pharma, Tokyo, Japan) was administered daily via a gastric gavage for 21 days. The dosages of BPS applied to the current experiments were determined according to studies elsewhere (22, 37) , and all rats tolerated well to the dosages. The BPS administration was started at the day of the first CSE injection. All rats were fed under the same conditions for 3 wk. At day 21 after starting the experiment, the rats were killed, and the blood samples and lung tissues were obtained as described below.
Sampling of Blood and Lung Tissues
At day 21 of the experiment, the rats were anesthetized with pentobarbital (50 mg/kg) intraperitoneally. The blood sample was taken from the inferior vena cava via the opened chest, collected into a polypropylene tube containing clot activator, and centrifuged at 3,000 g for 15 min. The serum was separated and stored at Ϫ70°C until the samples were assayed.
The left lung was inflated with 0.5% low melting agarose at a constant pressure of 25 cmH 2O and fixed in 10% formalin for 48 h. The paraffin-embedded sections from the same regions (upper and lower lobes) were used for histological examination. The right lung was homogenized immediately after harvest in a buffer containing 50 mM HEPES, 1 mM dithiothreitol, 0.1% Triton X-100, and 10% glycerol. The supernatant was separated after two cycles of centrifugation at 10,000 g for 10 min. The protein concentration in the supernatant was determined using the bicinchoninic acid protein assay (Pierce Biotechnology, Rockford, IL).
Morphological Assessment
The paraffin sections of the left lung were cut (thickness 3.5 m) and stained with hematoxylin and eosin (HE). Emphysematous changes were assessed by measurement of both the mean linear intercept (MLI) and the destructive index (DI). MLI is a measurement of mean interalveolar septal wall distance, which is widely used to examine alveolar space size. As previously described (9), the MLI was measured by dividing the length of a line drawn across the lung section by a total number of intercepts counted within this line at ϫ100 magnification. A total of 36 lines per each rat lung were drawn and measured. The DI was calculated to quantify the parenchymal destruction by using a microscopic point-count technique (29) . The analysis was performed in duplication with more than 3,000 alveoli randomly counted from 50 HE sections in each rat at ϫ200 magnification. Destructive alveolus was defined if at least one of the following alveoli was observed: alveolar wall defects; intraluminal parenchymal rags in alveolar ducts; obviously abnormal morphology; and typically emphysematous changes. The DI was calculated by dividing the defined destructive alveoli by the total number of alveoli counted and represented as percentage of the destructive alveoli as a fraction of total alveoli. The morphological assessment was repeated on coded samples.
Measurement of 6-Keto-PGF1␣ in Lung Tissues
The 6-keto-PGF1␣ is produced by the non-enzymatic hydration of PGI2 that has a half-life of only 2-3 min in buffer so that measurement of 6-keto-PGF1␣ is typically used to monitor the production of PGI2. In the present experiment, the levels of 6-keto-PGF1␣ in the supernatants of lung tissue homogenates in all rats were measured by competitive immunoassay using the Correlate-EIA 6-keto-PGF1␣ kit (Assay Designs, Ann Arbor, MI) in duplication according to the manufacturer's instructions. When the enzyme reaction was stopped, the colors generated were read on a microplate reader at 405 nm. The measured optical density was used to calculate the concentration of 6-keto-PGF1␣.
Apoptosis Assay
Measurement of the apoptotic index. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was performed to label the DNA-damaged cells in the lungs of experimental rats. The TACS 2 TdT DAB kit was purchased from Trevigen (Gaithersburg, MD) and used for this TUNEL experiment following the manufacturer's instructions. The apoptotic index (AI) was calculated as the percentage of TUNEL-positive nuclei in a total of more than 3,000 nuclei randomly counted for each lung at ϫ400 magnification.
Immunohistochemistry for activated caspase-3. The expression of activated caspase-3, a marker of apoptosis, was determined using a rabbit polyclonal antibody against the cleaved caspase-3 (Cell Signaling Technology, Danvers, MA) by immunohistochemistry according to the manufacturer's instructions.
Western blotting. The supernatant protein was electrophoresed on 14% SDS-PAGE (Invitrogen Life Technologies, Carlsbad, CA) at 125 V for 90 min and transferred electrophoretically on to a nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). The membrane was blocked and then rinsed and incubated with a rabbit polyclonal antibody against the cleaved caspase-3 (1:500, Cell Signaling Technology) overnight at 4°C. Following the incubation with the primary antibody, the membrane was carefully washed and reincubated for 1 h at room temperature with a secondary anti-rabbit antibody (1:1,000; R&D Systems, Minneapolis, MN). After washing, detection was performed using Quantity One 1-D Analysis Software (Bio-Rad Laboratories, Hercules, CA).
Gelatin Zymography
Matrix metalloproteinase (MMP)-2 and MMP-9 activities were determined by gelatin zymography (17) . Proteins from each lung extract were electrophoresed on 10% SDS-Tris-glycine gels containing 1 mg/ml gelatin (Invitrogen, Carlsbad, CA). SDS was removed from gels by shaking in 2.5% Triton X-100 twice for 1 h. The gels were then incubated overnight at 37°C in substrate buffer (50 mM Tris⅐HCl, pH 7.5, 5 mM CaCl 2, 0.5 M ZnCl2). Gels were stained with Coomassie brilliant blue and destained with methanol. Proteolysis bands were visualized and quantified using Printgraph (ATTO, Tokyo, Japan).
Measurements of TNF␣ and IL-1␤ in Lung Tissues
TNF␣ and IL-1␤ concentrations in the supernatants of lung homogenates were measured in duplication using commercially available ELISA kits (Quantikine Rat TNF␣ kit and Quantikine Rat IL-1␤ kit, R&D Systems, respectively) according to the manufacturer's instructions.
Measurements of Antioxidant Activity in Blood
The serum antioxidant activity was measured using the bioantioxidant power (BAP) test using the Free Radical Elective Evaluation FRAS4 system (Diacron International, Grosseto, Italy). The BAP test was performed in each rat according to the analysis procedure of the manufacturer's instructions. Briefly, 10 l of serum was dissolved in a solution, previously prepared by mixing FeCl 3 with a thiocyanate derivative solution. After a short incubation (5 min) at 37°C, this solution lost color, and the intensity of this chromic change was directly proportional to the serum reductive activity. Photometric reading was employed to assess the intensity of discoloration to evaluate the effective reduction activity or antioxidant potential. A lyophilized human control serum with known antioxidant activity (mol/l) was used for periodically calibrating the FRAS4 system. The results of the BAP test provided the serum biological antioxidant potential, which was expressed in mol/l.
Measurements of cAMP in Lung Tissues
To observe the cAMP, a ubiquitous second messenger involved in various cellular activations in many cell and tissue types, the cAMP levels were measured in duplication using commercially available ELISA kits (Quantikine Rat cAMP kit, R&D Systems) according to the manufacturer's instructions.
Statistical Analysis
A software package (SPSS 15.0; SPSS, Chicago, IL) was used to perform all statistical analyses. Continuous data were expressed as means Ϯ SD. Any differences among the four groups were evaluated by a one-way ANOVA. The Pearson's correlation was used to analyze the correlations of AI with the concentrations of serum TNF␣ and IL-1␤ separately. A P value less than 0.05 was considered statistically significant.
RESULTS
Morphological Findings
We confirmed a previously reported finding that intraperitoneal injection of CSE in rats caused emphysematous destruction of the lung within 3 wk (35) . Compared with the normal alveolar architecture (control group, Fig. 1Aa) , once a week injection of CSE for 3 wk induced enlargement of alveolar air spaces and destruction of lung parenchyma (CSE group, Fig.  1Ab ). The MLI and DI were significantly increased in the CSE group compared with the values in the control group (MLI: 108.7 Ϯ 6.8 m vs. 69.8 Ϯ 6.6 m, P Ͻ 0.0001; DI: 62.2 Ϯ 7.0% vs. 13.9 Ϯ 2.7%, P Ͻ 0.0001, respectively), indicating air space enlargement as a consequence of the CSE injection (Fig. 1B) . In contrast, BPS markedly inhibited the air space enlargement and the parenchyma destruction (Fig. 1A, c and d) . The MLI and DI were significantly reduced in the lungs in the BPS-1 group (MLI: 83.9 Ϯ 10.5 m, P Ͻ 0.0001; DI: 49.3 Ϯ 7.5%, P ϭ 0.002) and the BPS-2 group (MLI: 77.0 Ϯ 7.1 m, P Ͻ 0.0001; DI: 47.1 Ϯ 6.9%, P ϭ 0.001) compared with those in the CSE group (Fig. 1B) . However, the MLI and DI were not completely recovered to the values as those in control rats (P Ͻ 0.05 for MLI and DI in BPS-1 group and P Ͻ 0.05 for DI in BPS-2 group, compared with controls). There were no significant differences of the MLI and DI between the BPS-1 and BPS-2 groups (P Ͼ 0.05). In this regard, BPS only partially protected the lungs against alveolar space destruction as assessed by measuring the MLI and DI.
Levels of 6-Keto-PGF1␣ in Lung Tissues
We measured the stable metabolite of PGI 2 , 6-keto-PGF1␣, in lung tissues (Fig. 2) . As the amount of tissue in the emphysematous lung was decreased, the levels of 6-keto-PGF1␣ were expressed in relation to the quantity of protein in homogenates (g/mg). The concentration of 6-keto-PGF1␣ was significantly reduced in the lung tissues of the rats with CSE-induced emphysema (40.6 Ϯ 29.3 g/mg) compared with those of control rats (173.2 Ϯ 49.3 g/mg, P ϭ 0.001). BPS treatment markedly increased the level of 6-keto-PGF1␣ compared with that in CSE-injected rats (BPS-1: 134.4 Ϯ 52.1 g/mg, P ϭ 0.015; BPS-2: 432.9 Ϯ 71.5 g/mg, P Ͻ 0.0001). It is curious that the 6-keto PGF1␣ level in the high-dose BPS group was threefold higher than that in groups of control and low-dose BPS rats (P Ͻ0.001). Original magnifications, a-d, ϫ100 . B: morphometric measurements of MLI (m) and DI (%). *P Ͻ 0.05 compared with control group; †P Ͻ 0.05 compared with CSE group. Fig. 2 . 6-Keto-PGF1␣ level assessed by ELISA was decreased in the rats with CSE-induced emphysema compared with those of control rats, and BPS treatment markedly increased the level of 6-keto-PGF1␣ compared with CSE-injected rats. The levels of 6-keto-PGF1␣ were expressed in relation to the quantity of protein in homogenates (g/mg). *P Ͻ 0.05 compared with control group; †P Ͻ 0.05 compared with CSE group; §P Ͻ 0.01 compared with BPS-1 group.
Effect of BPS on Apoptosis in the Lung of Rats with Emphysema Induced by CSE
The TUNEL-positive (TUNEL ϩ ) cells were frequently localized in the peribronchiolar, intra-alveolar, and septal structures in the CSE-injected rats (Fig. 3Aa) with apoptotic alveolar epithelial cells in dominance (Fig. 4) . The TUNEL ϩ cells were quantified as AI by which the amount of DNA-damaged alveolar cells was identified to evaluate the apoptosis. The protective effect of BPS was related to a reduction in apoptosis as measured by AI (Fig. 3B) . The DNA-damaged cells were very rare in the normal rats (AI: 2.9 Ϯ 0.9%), whereas the TUNEL ϩ cells in CSE group were much more frequent (AI: 20.3 Ϯ 0.9%, P Ͻ 0.0001). BPS greatly reduced the number of TUNEL ϩ cells in the lungs of CSE-treated emphysematous rats (AI: 8.9 Ϯ 2.5% in BPS-1 group and 7.8 Ϯ 1.3% in BPS-2 group, P Ͻ 0.0001 vs. controls for each). Again, BPS treatment did not provide complete protection against apoptosis of the alveolar cells in rats treated with CSE.
Caspase-3, a marker of apoptosis, was analyzed by immunohistochemistry and Western blotting. Rats injected with CSE showed a large number of caspase-3 ϩ alveolar septal cells (arrows in Fig. 5Ab ) compared with the cells in the control (Fig. 5Aa) and BPS-treated rats (Fig. 5A, c and d) . The caspase-3 protein in the lung tissue measured by Western blot was expressed as a relative density of the caspase-3 to ␤-actin by the densitometry analysis. The protein levels of the cleaved form of caspase-3 were increased in the rats with CSE-induced emphysema (270.1 Ϯ 34.7%) compared with those of control rats (146.3 Ϯ 20.4%, P ϭ 0.012) (Fig. 5B) . In contrast, BPS treatment markedly reduced the protein level of cleaved caspase-3 compared with that in CSE-injected rats (BPS-1: 162.7 Ϯ 53.3%, P ϭ 0.023; BPS-2: 154.0 Ϯ 32.8%, P ϭ 0.016).
Effect of BPS on MMP-2 and MMP-9 Activity in the Lungs of Rats with Emphysema Induced by CSE
Prior studies showed an increased secretion and/or activity of MMP-2 and MMP-9 in bronchoalveolar lavage fluid (5), induced sputum (7), lung tissue (26) , and peripheral blood (21) in patients suffering from COPD, consistent with the concept that the proteolytic activity of MMPs is related to pulmonary inflammation, airway remodeling, and alveolar destruction. In accordance with these reports, rats injected with CSE showed increased MMP-2 and MMP-9 activities in their lung tissue homogenates (MMP-2: 215.2 Ϯ 33.5%, P ϭ 0.002; MMP-9: 190.5 Ϯ 60.0%, P ϭ 0.016) compared with the activity in the control rats (MMP-2: 98.2 Ϯ Original magnifications, a-d, ϫ400 . B: apoptosis index (AI) was calculated as described in MATERIALS AND METHODS. *P Ͻ 0.05 compared with control group; †P Ͻ 0.05 compared with CSE group. 38.4%, MMP-9: 84.1 Ϯ 29%) (Fig. 6, A and B) . MMP-2 and MMP-9 activities were reduced in the two BPS treatment groups, but statistical significance occurred in MMP-2 activity of both low-and high-dose BPS treatment rats (BPS-1: 148.1 Ϯ 45.3%, P ϭ 0.049; BPS-2: 116.8 Ϯ 53.3%, P ϭ 0.007, respectively) and in MMP-9 activity of only high-dose BPS treatment rats (97.3 Ϯ 40.6%, P ϭ 0.031).
Effect of BPS on Inflammation in the Lungs of Rats with Emphysema Induced by CSE
To examine whether the emphysema-protective effect of BPS was associated with an anti-inflammatory effect on the rats after CSE injection, we measured the levels of TNF␣ and IL-1␤ in the lung tissues. As the amount of tissue in the emphysematous lung was decreased, the levels of TNF␣ and IL-1␤ were expressed in relation to the quantity of protein in homogenates (pg/mg). As shown in Fig. 7A , the levels of TNF␣ and IL-1␤ were significantly increased in the CSE group (11.4 Ϯ 1.4 pg/mg, P Ͻ 0.0001 and 214.4 Ϯ 52.7 pg/mg, P ϭ 0.022, respectively) compared with those in controls (8.3 Ϯ 1.0 pg/mg and 131.4 Ϯ 36.2 pg/mg, respectively). And high-dose (200 g⅐kg Ϫ1 ⅐day
Ϫ1
) BPS treatment significantly reduced the levels of TNF␣ and IL-1␤ in the lungs of CSE-treated emphysematous rats. As shown in Fig. 7B , the levels of TNF␣ and IL-1␤ were positively correlated with the AI in the lungs of all rats including the control rats and emphysema rats induced by CSE injection (r ϭ 0.657, P Ͻ 0.0001 and r ϭ 0.530, P ϭ 0.008, respectively).
Effect of BPS on Antioxidant Activity in the Serum of Rats with Emphysema Induced by CSE
We also examined whether the protective effect of BPS of rats after CSE injection was associated with a reduction in biological antioxidant activity (Fig. 8) . The serum antioxidant activity was significantly decreased in the CSE-treated rats (1,653.4 Ϯ 504.7 mol/l, P ϭ 0.01) compared with the control rats (2,438.9 Ϯ 235.6 mol/l). BPS treatment significantly prevented the reduction of antioxidant activity in rats injected with CSE (BPS-1: 2,420 Ϯ 434.4 mol/l, P ϭ 0.011; BPS-2: 2,344.8 Ϯ 664.6 mol/l, P ϭ 0.026, compared with CSE group).
BPS Enhanced cAMP Levels in Lung Tissues of Rats with Emphysema Induced by CSE
We suspected that the cAMP pathway was the most likely molecular downstream signaling in the cellular events that occurred in BPS prevention of emphysema in rats induced by injection of CSE based on studies elsewhere (14 -16) . The levels of cAMP were expressed in relation to the quantity of protein in homogenates (g/mg). The cAMP levels were 2.31 Ϯ 1.04 g/mg in the lung tissues of the BPS-1 group and 3.83 Ϯ 2.83 g/mg in the BPS-2 group, in contrast to the undetectable cAMP levels in both the control rats and CSEinjected rats (less than 1.05 g/mg).
DISCUSSION
The most remarkable finding of this study is that the stable PGI 2 analog BPS prevented the development of emphysema in Fig. 7 . TNF␣ and IL-1␤ measurements in lung tissues by ELISA. A: the levels of TNF␣ and IL-1␤ were increased in the CSE group compared with the control and BPS-2 groups, whereas there were no significant differences between the CSE group and the BPS-1 group. The levels of TNF␣ and IL-1␤ were expressed in relation to the quantity of protein in homogenates (pg/mg). *P Ͻ 0.05 compared with control group; †P Ͻ 0.05 compared with CSE group; §P Ͻ 0.05 compared with BPS-1 group. B: the level of TNF␣ in the lung tissue positively correlated with AI in the lung of rats (r ϭ 0.657, P Ͻ 0.0001), and the level of IL-1␤ in the lung tissue positively correlated with AI in the lung of rats (r ϭ 0.530, P ϭ 0.008).
this rat model, which is induced by a systemic CSE challenge. BPS protected against the experimental emphysema by the inhibition of lung alveolar septal cell apoptosis, reductions of MMP-9 and MMP-2 activation, and inflammatory cytokine levels in rats with CSE-induced emphysema.
Whereas systemic CSE injection caused enlargement of the alveolar air spaces by 35% and an increase in the levels of activated casepase-3 in whole rat lung tissue extracts (35) , and replication of this model in mice (34) confirmed the efficiency and effect of the CSE injection in establishing a smokingrelated rodent emphysema model, it is unclear whether all pathobiologically relevant mechanisms in this model are shared with the conventional models where cigarette smoke is inhaled over a period of several months. The mechanism in this novel animal emphysema model is not completely known but thought to be involved with autoimmune mechanisms in alveolar septal cell destruction (2, 33) . Nevertheless, the systemic delivery of CSE generated enlargement of the air spaces and alveolar destruction in rats within 3 wk.
Although we did not conduct a detailed exploration, DNA damage of alveolar cells and caspase-3 expression, either as a direct effect of noxious components of CSE and/or as a consequence of inflammation, were decreased in the emphysematous lungs of rats treated with BPS. A recent in vitro study demonstrated that cigarette smoke suppressed PGI 2 S and that pulmonary endothelial PGI 2 S expression was decreased in the arteriolar endothelium in emphysema, and lung-specific overexpression of PGI 2 S resulted in a decrease in caspase-3 activity after long-term smoke exposure in a transgenic murine model (24) . Aoshiba et al. (3) also reported that intratracheal administration of active caspase-3 resulted in epithelial apoptosis, enhanced elastolytic activity in the lung, and development of emphysematous changes in mice. Our results revealed that 6-keto-PGF1␣ was significantly decreased in the lungs of emphysematous rats and that BPS treatment significantly increased the levels of 6-keto-PGF1␣ that is a production of endogenous PGI 2 by non-enzymatic hydration. The high-dose BPS raised 6-keto-PGF1␣ levels to a supernormal level, probably due to a nonlinear correlation of the 6-keto-PGF1␣ with the endogenous PGI 2 . Administration of BPS, a PGI 2 analog, may supply PGI 2 to emphysematous rats that are in deficiency in PGI 2 . It is also possible that the BPS prevented apoptosis of PGI synthase-expressing cells that might have been damaged by CSE through activating the PGI 2 receptor. The present results demonstrated that the BPS protected against emphysema formation and decreased apoptosis and expression of caspase-3 activity. The inhibition of apoptosis by BPS treatment is consonant with the evidence supporting that PGI 2 has antiapoptotic effects in other organ systems (8, 11) .
BPS, the stable PGI 2 analog, causes relaxation of vascular smooth muscle in most blood vessels (14, 23, 37) and inhibits platelet aggregation (12, 15) . The properties of vasodilatation and antithrombosis may help to protect against pathological changes in the small pulmonary arteries of patients with pulmonary hypertension (14, 23, 37) . Beyond the vasodilatation, PBS also modulates tissue remodeling by affecting fibroblastmediated contraction of extracellular matrix protein production in fibroblasts (16) and human cultured mesangial cells (18) , and diminishes the amounts of cytokines such as IL-1, IL-6, and TNF␣ produced by alveolar macrophages in the development of pulmonary hypertension (23) . Our present in vivo study similarly demonstrates significant suppressions of MMP-9 and MMP-2 activities and reductions in TNF␣ and IL-1␤ in the BPS-treated lungs with emphysema. Attenuation of proteolytic enzymes, such as MMP-2 and MMP-9, may inhibit one of the mechanisms of lung tissue remodeling in COPD, whereby MMPs degrade collagen and elastin, regulate extracellular matrix deposition, and contribute to cell migration and proliferation (4, 6). Kitahara and colleagues (18) demonstrated that the prostacyclin inhibits the production of MMP-9 induced by phorbol ester through protein kinase A activation in human cultured mesangial cells. Similarly, reduction of the inflammatory cytokines, for example, TNF␣ and IL-1␤, may dampen the inflammation contributing to the development of COPD (10) . In addition, we found a normal biological antioxidant activity in the serum of CSE-treated rats after administration of BPS. Ohmori et al. (25) demonstrated that BPS decreases the polymorphonuclear leukocyte-induced superoxide anion (O 2 Ϫ ) production and serum superoxide dismutase activity in spontaneously hypertensive rats, suggesting that BPS had merit for preventing the O 2 Ϫ -related organ damage. Adderley and Fitzgerald (1) showed that the oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. Shinmura et al. (30) reported that prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K ϩ channels via the EP3 receptor. In our case, we suspect that the normal biological antioxidant activity after administration of BPS is probably related to the inhibitory effect of BPS on inflammation in this model. However, it is important to note that we were only able to show a protective, but not a curative, effect of BPS in this experimental rat model.
BPS is a potent vasodilator whose biological effects are believed to be mediated by cAMP (14, 32) . PGI 2 and its stable analogs activate a specific cell-surface receptor (IP receptor, IPR), which is coupled to adenylyl cyclase through G s protein.
Elevation of cAMP levels has been considered to be a key cellular event to trigger blood vessel relaxation by IP agonists. BPS, an IP agonist, elicited a vascular relaxation by activating Fig. 8 . Antioxidant activity measurement of serum in the rats by biological antioxidant power (BAP) test. The antioxidant activity in the CSE group was significantly lower than those of control and BPS treatment groups, whereas there were no differences between the control and BSP treatment groups. *P Ͻ 0.05 compared with control group; †P Ͻ 0.05 compared with CSE group.
IPR through a cAMP-dependent pathway. Moreover, BPS modulates tissue remodeling by affecting fibroblast-mediated contraction of extracellular matrix through activating the cAMP-dependent protein kinase A pathway (16) . In this emphysema model of rats induced by injection of CSE, BPS significantly improved the emphysematous molecular pathologies with an enhancement of cAMP levels in the lung tissues. It seems likely that, similar to the signaling events in relaxation of blood vessels (14, 32) , modulation of tissue remodeling (16) , and reduction of thrombolic events (15) , BPS generates the identified molecular preventive events in emphysematous lungs through activating cAMP downstream signaling.
In conclusion, we have shown in this study that BPS, an orally PGI 2 analog, protects against the development of CSEinduced emphysema in rats by attenuating apoptosis, inhibiting proteolytic enzyme activities, reducing inflammatory cytokines, and augmenting serum antioxidant activity. BPS may represent a new therapeutic option in the prevention of emphysema in humans in prospect.
